Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.28, read 2026-11-02
Ethical does not pass the values gate
Price60.07 USD
Fair value71.29
Ethical score70.0/100
Value readUndervaluedas of 5 Nov 2026
Our investment reviews on this name
2026-10-21Read Markup52.96+13.4% to today ✓Distribution gives way to Markup after a 27% rise in 3 weeks
2026-10-02Read Distribution41.85+43.5% to today Markup gives way to Distribution after a 21% slide in 3 weeks
2026-09-09Read Markup53.29+12.7% to today ✓Distribution gives way to Markup
2026-07-02Read Distribution51.01+17.8% to today First review on file: Distribution
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Planet Fitness, Inc. holds its Markup at $60.07. Consolidating, no directional conviction, held for 61 days.
As held on the ledger · 2026-11-05
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 61 days
Price at the screen
$60.07
Valuation
19.50 trailing · 15.65 forward price to earnings
Values screen
FAIL· score 70.0
Beta
1.03
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
93.49%
Below 33%
Interest-bearing debt is 93.5% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
2.84%
Below 33%
Cash held in interest-bearing accounts and securities is 2.8% of assets, under the one-third limit.
Pass
Receivables
13.41%
Below 49%
Money owed to the company is 13.4% of assets, under the 49% limit.
Pass
Revenue purity
1.74%
Below 5%
Only 1.7% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Planet Fitness,'s business is in a permissible area, but its interest-bearing debt is about 93% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when PLNT's ethical verdict changes
Today PLNT does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 5 Nov 2026: it trades at roughly a 20% discount to our $71.29 fair value, 4.50% revenue growth.
Fair value range in USD, drawn from the 2026-11-05 screen. The gold marker is the market price at the same screen. A 15.7% discount to the base estimate.
Where our models see it going: fair-value estimate $71.29, with a range of $60.44 to $100.73, dated to the 2026-11-05 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Cheap gym chain with growth yet we pass
Walk into any Planet Fitness and the low fees pull in crowds who might otherwise skip the gym. Revenue is climbing 20% and margins sit at 18% with a forward multiple of just 14.6 times, while the ethical screen raises no flags. The setup looks tidy on paper.
Yet the opportunity rating stays at none. Unknown moat, heavy reliance on consumer wallets in a cyclical leisure sector, and analyst targets clustered around 62 dollars all point to limited edge once spending patterns shift. Fair value sits higher at 70 dollars but that gap alone does not override the structural caution.
Risk sits in the cyclical exposure and thin differentiation, where any slowdown in discretionary fitness spend could compress both growth and multiples quickly. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
PLNT trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-05Markup$57.34+4.2%Entry 17
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 4.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 50%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (19 analysts) rates it buy, with a mean price target of $67. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-04Markup$55.03+2.7%Entry 16
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 2.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 50%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (19 analysts) rates it buy, with a mean price target of $67. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-03Markup$53.58+0.0%Entry 15
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 50%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (19 analysts) rates it buy, with a mean price target of $67. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-02Markup$53.58+0.0%Entry 14
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 50%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (19 analysts) rates it buy, with a mean price target of $67. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-01Markup$53.58+2.0%Entry 13
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 2.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 50%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (19 analysts) rates it buy, with a mean price target of $67. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-31Markup$52.52+0.0%Entry 12
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 50%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (19 analysts) rates it buy, with a mean price target of $67. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-30Markup$52.52+0.0%Entry 11
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 50%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (19 analysts) rates it buy, with a mean price target of $67. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29Markup$52.52-0.8%Entry 10
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 50%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (19 analysts) rates it buy, with a mean price target of $67. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28Markup$52.96+0.0%Entry 9
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 50%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (19 analysts) rates it buy, with a mean price target of $67.
2026-10-21Markup · changed$52.96+10.4%Entry 8
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 10.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 50%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (19 analysts) rates it buy, with a mean price target of $67.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
